ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
enGene Therapeutics Inc.
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026
$1.58−0.09 (-5.39%)
Close on Oct 19, 2026
- Market cap
- $110.18M
- P/E (TTM)
- 0.7
- Dividend yield
- 0.00%
enGene Therapeutics Inc. cash flow statement
Ratios
Latest available, balances at Jul 31, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -53.3%
Financial strength
- Current ratio
- 10.21
- Debt to equity
- 0.11
- Debt to assets
- 8.7%
- Cash to current liabilities
- 150.8%
Valuation
- P/E ratio
- 0.7
- Price to sales
- –
- Price to book
- 0.48
- Dividend yield
- 0.00%